Article
US FDA declines to approve Regeneron's higher-dose Eylea, shares tumble
Rating:
0.0
Views:
64
Likes:
1
Library:
1
U.S. health regulators on Tuesday declined to approve a higher-dose version of Regeneron Pharmaceuticals' drug Eylea for treatment of a disease that is leading cause of blindness among the elderly, the company said as shares fell on the setback to its effort to defend the blockbuster treatment against a fast-gaining rival.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value